Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Characterizing Parental Use of a HIPAA-Compliant Large Language Model Chatbot in Rare Pediatric Diseases: Insights from Think-Aloud Sessions.

Applied clinical informatics·2026

Same author

A single-institution retrospective study of multicentric gliomas stratified by <i>IDH</i> mutational status.

Neuro-oncology advances·2026

Same author

Development and characterization of triazole-based WDR5 inhibitors for the treatment of glioblastoma.

JCI insight·2026

Same author

Clinical and radiographic prognostic factors in recurrent contrast-enhancing IDH-mutant gliomas treated with bevacizumab.

Neuro-oncology advances·2026

Same author

Beyond cell cycle control: <i>CDKN2A</i> loss is associated with altered NAD<sup>+</sup> metabolic states and increased sensitivity to NAMPT inhibition in glioblastoma.

Neuro-oncology advances·2026

Same author

Platelets regulate glioblastoma growth and immunity via sex-dependent PAR4 - Estrogen receptor beta signaling.

bioRxiv : the preprint server for biology·2026

Search research articles

Related Experiment Video

Updated: Apr 23, 2026

Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma

Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma

Published on: January 19, 2024

Modeling Gliomas with Organoids: Classification, Fidelity, and Guidelines for Translational Neuro-Oncology.

Christopher G Hubert^1,2, Renee D Read^3,4,5, Tyler E Miller^2,6,7

¹Department of Biochemistry, Case Western Reserve University, Cleveland, Ohio, USA.

|April 22, 2026

Summary

Glioma organoid models offer advanced preclinical research platforms. This review categorizes models, proposes nomenclature, and calls for standardization to improve neuro-oncology research.

Keywords:

Glioma organoids Preclinical models Standardization and nomenclature Translational neuro-oncology Tumor microenvironment

More Related Videos

Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases

Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases

Published on: June 28, 2019

Maintaining Human Glioblastoma Cellular Diversity Ex vivo using Three-Dimensional Organoid Culture

Maintaining Human Glioblastoma Cellular Diversity Ex vivo using Three-Dimensional Organoid Culture

Published on: August 25, 2022

Related Experiment Videos

Last Updated: Apr 23, 2026

Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma

Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma

Published on: January 19, 2024

Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases

Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases

Published on: June 28, 2019

Maintaining Human Glioblastoma Cellular Diversity Ex vivo using Three-Dimensional Organoid Culture

Maintaining Human Glioblastoma Cellular Diversity Ex vivo using Three-Dimensional Organoid Culture

Published on: August 25, 2022

Area of Science:

Neuro-oncology
Biomedical Engineering
Translational Research

Background:

Organoid technology advancements revolutionize glioma modeling.
FDA and NIH initiatives support human-relevant organoid platforms.
Glioma organoids provide a human cell-relevant framework for research.

Purpose of the Study:

To provide a comprehensive overview of glioma organoid models.
To offer guidance on selecting appropriate models and readouts.
To propose a nomenclature framework for glioma organoid models.

Main Methods:

Categorization of glioma organoids into engineered, patient-tissue derived, and assembloids.
Review of applications in IDH-mutant gliomas and DMGs.
Discussion of challenges and innovations in organoid technology.

Main Results:

Glioma organoids offer distinct strengths for modeling gliomagenesis and tumor-microenvironment interactions.
A proposed nomenclature framework enhances clarity and communication.
Identified challenges include scalability, standardization, and vascularization.

Conclusions:

Glioma organoid models are crucial for investigating glioma biology and therapeutic responses.
Standardization and collaboration are essential for integrating organoids into translational pipelines.
Further development is needed to refine preclinical modeling in neuro-oncology.